Company intelligence / Profile preview

CryoHoldco

Ownership: Private
Development stage: Commercial

Overview

CryoHoldco has conducted over 16,500 treatments and manages over 325,000 stored samples. The company has also managed clinical trials in various countries for COVID-19 treatment using mesenchymal stem cells derived from Wharton's jelly[1].

Therapeutic areas: OtherInfectious Diseases
Modalities: Stem cell-based treatmentsRegenerative medicine
Industry: Biotech

Beyond the preview

Go deeper on CryoHoldco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CryoHoldco.

Explore the full profile